Outcomes Data For Pfizer's Inspra Could Give Heart Failure Drug A Jumpstart
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer's Inspra has been a commercial flop, but now a post-marketing study has shown positive results in a broader patient population